Blog

Aug 9, 2023

Frequency Change: Korro Bio Edits Its Message, Rewrites Its Future with Reverse Merger

Posted by in categories: biotech/medical, futurism

Korro Bio plans a reverse merger with Frequency Therapeutics to fund clinical studies of its lead candidate, designed to treat alpha-1 antitrypsin deficiency (AATD) in the liver.

1

Comment so far


  1. only up game says:

    Alpha-1 antitrypsin deficiency is a genetic disorder that can lead to liver disease and lung complications. Currently, there are limited treatment options available for this condition, making the development of new therapies a crucial endeavor. Korro Bio’s lead candidate holds promise in addressing this unmet medical need.

Leave a reply